Search

Sirdalud

Sirdalud

tizanidine

Manufacturer:

Novartis Healthcare

Distributor:

Zuellig

Marketer:

Sandoz
Concise Prescribing Info
Contents
Tizanidine HCl
Indications/Uses
Painful muscle spasms associated w/ static & functional disorders of the spine (cervical & lumbar syndromes) &/or following surgery eg, for herniated intervertebral disc or OA of the hip. Spasticity due to neurological disorders eg, multiple sclerosis, chronic myelopathy, degenerative spinal cord diseases, CVA & cerebral palsy.
Click to view Sirdalud detailed prescribing information
Dosage/Direction for Use
Relief of painful muscle spasms 2-4 mg tid. Severe cases 2 or 4 mg extra dose. Spasticity due to neurological disorders Initially 6 mg daily in 3 divided doses, may increase stepwise at half-wkly or wkly intervals by 2-4 mg. Optimum therapeutic response: 12 & 24 mg daily in 3 or 4 equally spaced doses. Max: 36 mg daily. Renal impairment (CrCl <25 mL/min) Initially 2 mg once daily.
Click to view Sirdalud detailed prescribing information
Overdosage
View Sirdalud overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Severely impaired hepatic function. Concomitant use w/ strong CYP1A2 inhibitors eg, fluvoxamine or ciprofloxacin.
Click to view Sirdalud detailed prescribing information
Special Precautions
Drugs known to increase QT interval. Hypotension. Avoid abrupt w/drawal. Discontinue use if SGPT/SGOT levels are persistently >3x the upper limit of normal; monitor liver function test (≥12 mg dose). Renal impairment (CrCl <25 mL/min). May impair ability to drive or operate machinery. Pregnancy & lactation. Not recommended in childn ≤18 yr. Elderly ≥65 yr.
Click to view Sirdalud detailed prescribing information
Adverse Reactions
Somnolence, dizziness; GI disorder, dry mouth; muscular weakness; fatigue. Insomnia, sleep disorder; hypotension; nausea; decreased BP, increased transaminases.
Click to view Sirdalud detailed prescribing information
Drug Interactions
Increased plasma levels & QT(c) prolongation w/ CYP1A2 inhibitors [eg, fluvoxamine or ciprofloxacin, antiarrhythmics (amiodarone, mexiletine, propafenone), cimetidine, fluoroquinolones (enoxacin, pefloxacin, norfloxacin), rofecoxib, OCs & ticlopidine]. Decreased plasma levels w/ CYP1A2 inducers. Drugs known to prolong QT interval (eg, cisapride, amytriptyline & azithromycin). May occasionally cause hypotension & bradycardia w/ antihypertensives including diuretics. Decreased conc w/ rifampicin. Decrease systemic exposure in smokers (>10 cigarettes/day). May enhance CNS depressant effects of alcohol. May enhance sedative action w/ sedatives, hypnotics (eg, benzodiazepines or baclofen) & antihistamines. Potential additive hypotensive effect w/ α-2 adrenergic agonists (eg, clonidine).
Click to view Sirdalud detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Sirdalud detailed prescribing information
Storage
View Sirdalud storage conditions for details to ensure optimal shelf-life.
Description
View Sirdalud description for details of the chemical structure and excipients (inactive components).
Action
View Sirdalud mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Muscle Relaxants
ATC Classification
M03BX02 - tizanidine ; Belongs to the class of other centrally-acting muscle relaxants.
Presentation/Packing
Form
Sirdalud tab 2 mg
Packing/Price
50's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in